Target intelligence / Profile preview

Norovirus Genogroup I Genotype 1 Major Capsid Protein VP1 (VP1)

Target
VP1
Molecular classification
Viral structural protein, Capsid protein
01

Overview

The Norovirus GI.1 VP1 major capsid protein is the primary structural unit of the Norwalk virus, the prototype strain of the Norovirus genus (UniProt P03313). It consists of 180 subunits that self-assemble to form an icosahedral capsid, organized into a conserved Shell (S) domain and a variable Protruding (P) domain. The P domain is further divided into P1 and P2 subdomains, with P2 being the most surface-exposed region responsible for binding to histo-blood group antigens (HBGAs), which act as essential attachment factors for host cell entry. Because it mediates host-cell interaction and contains the major neutralizing epitopes, VP1 is the central target for vaccine development, typically formulated as virus-like particles (VLPs) or delivered via viral vectors. Therapeutic strategies focus on inducing neutralizing antibodies that block the P2 domain's ability to bind HBGAs, thereby preventing infection. Current clinical candidates like TAK-214 utilize recombinant VP1 VLPs to elicit protective immune responses against GI.1 and GII.4 strains (NCT03039751).

Other names
Major capsid proteinVP1Shell proteinProtruding domain proteinNorwalk virus VP1Capsid protein VP1
02

Mechanism of action

Induction of neutralizing antibodies that block the interaction between the VP1 protruding domain and host histo-blood group antigens (HBGAs), thereby preventing viral attachment and entry.

03

Biological functions

Viral entryViral assemblyHost cell bindingAntigenicityReceptor binding
04

Disease associations

GastroenteritisInfection
05

Safety considerations

High genetic diversity and antigenic drift of norovirus strainsShort-lived natural and vaccine-induced immunityPotential for strain-specific protection rather than broad-spectrum immunity across genogroupsVaccine-induced reactogenicity (e.g., injection site pain, fever)
06

Interacting drugs

TAK-214 (Norovirus VLP vaccine candidate)

2 more in the full profile.

07

Biomarkers

Anti-VP1 IgG titersAnti-VP1 IgA titersHBGA-blocking antibody (BT50) titersFecal viral load

Beyond the preview

Go deeper on Norovirus Genogroup I Genotype 1 Major Capsid Protein VP1 (VP1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Norovirus Genogroup I Genotype 1 Major Capsid Protein VP1 (VP1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call